The endogenous preproglucagon system is not essential for gut growth homeostasis in mice

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

The endogenous preproglucagon system is not essential for gut growth homeostasis in mice. / Wismann, Pernille; Barkholt, Pernille; Secher, Thomas; Vrang, Niels; Hansen, Henrik B; Jeppesen, Palle Bekker; Baggio, Laurie L; Koehler, Jacqueline A; Drucker, Daniel J; Sandoval, Darleen A; Jelsing, Jacob.

I: Molecular Metabolism, Bind 6, Nr. 7, 07.2017, s. 681-692.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Wismann, P, Barkholt, P, Secher, T, Vrang, N, Hansen, HB, Jeppesen, PB, Baggio, LL, Koehler, JA, Drucker, DJ, Sandoval, DA & Jelsing, J 2017, 'The endogenous preproglucagon system is not essential for gut growth homeostasis in mice', Molecular Metabolism, bind 6, nr. 7, s. 681-692. https://doi.org/10.1016/j.molmet.2017.04.007

APA

Wismann, P., Barkholt, P., Secher, T., Vrang, N., Hansen, H. B., Jeppesen, P. B., ... Jelsing, J. (2017). The endogenous preproglucagon system is not essential for gut growth homeostasis in mice. Molecular Metabolism, 6(7), 681-692. https://doi.org/10.1016/j.molmet.2017.04.007

Vancouver

Wismann P, Barkholt P, Secher T, Vrang N, Hansen HB, Jeppesen PB o.a. The endogenous preproglucagon system is not essential for gut growth homeostasis in mice. Molecular Metabolism. 2017 jul;6(7):681-692. https://doi.org/10.1016/j.molmet.2017.04.007

Author

Wismann, Pernille ; Barkholt, Pernille ; Secher, Thomas ; Vrang, Niels ; Hansen, Henrik B ; Jeppesen, Palle Bekker ; Baggio, Laurie L ; Koehler, Jacqueline A ; Drucker, Daniel J ; Sandoval, Darleen A ; Jelsing, Jacob. / The endogenous preproglucagon system is not essential for gut growth homeostasis in mice. I: Molecular Metabolism. 2017 ; Bind 6, Nr. 7. s. 681-692.

Bibtex

@article{6133e84968ba45fa80b119c0391b86cf,
title = "The endogenous preproglucagon system is not essential for gut growth homeostasis in mice",
abstract = "OBJECTIVE: The prevalence of obesity and related co-morbidities is reaching pandemic proportions. Today, the most effective obesity treatments are glucagon-like peptide 1 (GLP-1) analogs and bariatric surgery. Interestingly, both intervention paradigms have been associated with adaptive growth responses in the gut; however, intestinotrophic mechanisms associated with or secondary to medical or surgical obesity therapies are poorly understood. Therefore, the objective of this study was to assess the local basal endogenous and pharmacological intestinotrophic effects of glucagon-like peptides and bariatric surgery in mice.METHODS: We used in situ hybridization to provide a detailed and comparative anatomical map of the local distribution of GLP-1 receptor (Glp1r), GLP-2 receptor (Glp2r), and preproglucagon (Gcg) mRNA expression throughout the mouse gastrointestinal tract. Gut development in GLP-1R-, GLP-2R-, or GCG-deficient mice was compared to their corresponding wild-type controls, and intestinotrophic effects of GLP-1 and GLP-2 analogs were assessed in wild-type mice. Lastly, gut volume was determined in a mouse model of vertical sleeve gastrectomy (VSG).RESULTS: Comparison of Glp1r, Glp2r, and Gcg mRNA expression indicated a widespread, but distinct, distribution of these three transcripts throughout all compartments of the mouse gastrointestinal tract. While mice null for Glp1r or Gcg showed normal intestinal morphology, Glp2r-/- mice exhibited a slight reduction in small intestinal mucosa volume. Pharmacological treatment with GLP-1 and GLP-2 analogs significantly increased gut volume. In contrast, VSG surgery had no effect on intestinal morphology.CONCLUSION: The present study indicates that the endogenous preproglucagon system, exemplified by the entire GCG gene and the receptors for GLP-1 and GLP-2, does not play a major role in normal gut development in the mouse. Furthermore, elevation in local intestinal and circulating levels of GLP-1 and GLP-2 achieved after VSG has limited impact on intestinal morphometry. Hence, although exogenous treatment with GLP-1 and GLP-2 analogs enhances gut growth, the contributions of endogenously-secreted GLP-1 and GLP-2 to gut growth may be more modest and highly context-dependent.",
author = "Pernille Wismann and Pernille Barkholt and Thomas Secher and Niels Vrang and Hansen, {Henrik B} and Jeppesen, {Palle Bekker} and Baggio, {Laurie L} and Koehler, {Jacqueline A} and Drucker, {Daniel J} and Sandoval, {Darleen A} and Jacob Jelsing",
year = "2017",
month = "7",
doi = "10.1016/j.molmet.2017.04.007",
language = "English",
volume = "6",
pages = "681--692",
journal = "Molecular Metabolism",
issn = "2212-8778",
publisher = "Elsevier",
number = "7",

}

RIS

TY - JOUR

T1 - The endogenous preproglucagon system is not essential for gut growth homeostasis in mice

AU - Wismann, Pernille

AU - Barkholt, Pernille

AU - Secher, Thomas

AU - Vrang, Niels

AU - Hansen, Henrik B

AU - Jeppesen, Palle Bekker

AU - Baggio, Laurie L

AU - Koehler, Jacqueline A

AU - Drucker, Daniel J

AU - Sandoval, Darleen A

AU - Jelsing, Jacob

PY - 2017/7

Y1 - 2017/7

N2 - OBJECTIVE: The prevalence of obesity and related co-morbidities is reaching pandemic proportions. Today, the most effective obesity treatments are glucagon-like peptide 1 (GLP-1) analogs and bariatric surgery. Interestingly, both intervention paradigms have been associated with adaptive growth responses in the gut; however, intestinotrophic mechanisms associated with or secondary to medical or surgical obesity therapies are poorly understood. Therefore, the objective of this study was to assess the local basal endogenous and pharmacological intestinotrophic effects of glucagon-like peptides and bariatric surgery in mice.METHODS: We used in situ hybridization to provide a detailed and comparative anatomical map of the local distribution of GLP-1 receptor (Glp1r), GLP-2 receptor (Glp2r), and preproglucagon (Gcg) mRNA expression throughout the mouse gastrointestinal tract. Gut development in GLP-1R-, GLP-2R-, or GCG-deficient mice was compared to their corresponding wild-type controls, and intestinotrophic effects of GLP-1 and GLP-2 analogs were assessed in wild-type mice. Lastly, gut volume was determined in a mouse model of vertical sleeve gastrectomy (VSG).RESULTS: Comparison of Glp1r, Glp2r, and Gcg mRNA expression indicated a widespread, but distinct, distribution of these three transcripts throughout all compartments of the mouse gastrointestinal tract. While mice null for Glp1r or Gcg showed normal intestinal morphology, Glp2r-/- mice exhibited a slight reduction in small intestinal mucosa volume. Pharmacological treatment with GLP-1 and GLP-2 analogs significantly increased gut volume. In contrast, VSG surgery had no effect on intestinal morphology.CONCLUSION: The present study indicates that the endogenous preproglucagon system, exemplified by the entire GCG gene and the receptors for GLP-1 and GLP-2, does not play a major role in normal gut development in the mouse. Furthermore, elevation in local intestinal and circulating levels of GLP-1 and GLP-2 achieved after VSG has limited impact on intestinal morphometry. Hence, although exogenous treatment with GLP-1 and GLP-2 analogs enhances gut growth, the contributions of endogenously-secreted GLP-1 and GLP-2 to gut growth may be more modest and highly context-dependent.

AB - OBJECTIVE: The prevalence of obesity and related co-morbidities is reaching pandemic proportions. Today, the most effective obesity treatments are glucagon-like peptide 1 (GLP-1) analogs and bariatric surgery. Interestingly, both intervention paradigms have been associated with adaptive growth responses in the gut; however, intestinotrophic mechanisms associated with or secondary to medical or surgical obesity therapies are poorly understood. Therefore, the objective of this study was to assess the local basal endogenous and pharmacological intestinotrophic effects of glucagon-like peptides and bariatric surgery in mice.METHODS: We used in situ hybridization to provide a detailed and comparative anatomical map of the local distribution of GLP-1 receptor (Glp1r), GLP-2 receptor (Glp2r), and preproglucagon (Gcg) mRNA expression throughout the mouse gastrointestinal tract. Gut development in GLP-1R-, GLP-2R-, or GCG-deficient mice was compared to their corresponding wild-type controls, and intestinotrophic effects of GLP-1 and GLP-2 analogs were assessed in wild-type mice. Lastly, gut volume was determined in a mouse model of vertical sleeve gastrectomy (VSG).RESULTS: Comparison of Glp1r, Glp2r, and Gcg mRNA expression indicated a widespread, but distinct, distribution of these three transcripts throughout all compartments of the mouse gastrointestinal tract. While mice null for Glp1r or Gcg showed normal intestinal morphology, Glp2r-/- mice exhibited a slight reduction in small intestinal mucosa volume. Pharmacological treatment with GLP-1 and GLP-2 analogs significantly increased gut volume. In contrast, VSG surgery had no effect on intestinal morphology.CONCLUSION: The present study indicates that the endogenous preproglucagon system, exemplified by the entire GCG gene and the receptors for GLP-1 and GLP-2, does not play a major role in normal gut development in the mouse. Furthermore, elevation in local intestinal and circulating levels of GLP-1 and GLP-2 achieved after VSG has limited impact on intestinal morphometry. Hence, although exogenous treatment with GLP-1 and GLP-2 analogs enhances gut growth, the contributions of endogenously-secreted GLP-1 and GLP-2 to gut growth may be more modest and highly context-dependent.

U2 - 10.1016/j.molmet.2017.04.007

DO - 10.1016/j.molmet.2017.04.007

M3 - Journal article

C2 - 28702324

VL - 6

SP - 681

EP - 692

JO - Molecular Metabolism

JF - Molecular Metabolism

SN - 2212-8778

IS - 7

ER -

ID: 196342844